Infusion-related reactions to rituximab: frequency, mechanisms and predictors

Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions

(2018) Seyed Moein Moghimi   DRUG DISCOVERY TODAY

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

(2017) Giovanni D’Arena et al.   LEUKEMIA & LYMPHOMA

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

(2017) Robert Marcus et al.   NEW ENGLAND JOURNAL OF MEDICINE

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas

(2017) Tatsuya Hayama et al.   International Journal of Clinical Pharmacy

Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms

(2017) Johnson T. Wong et al.   Journal of Allergy and Clinical Immunology-In Practice

The clinical development of obinutuzumab for the treatment of follicular lymphoma

(2017) Barbara Ma et al.   Cancer Management and Research

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

(2016) C L Freeman et al.   LEUKEMIA

A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas

(2015) Pierre Feugier   Future Oncology

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study

(2015) Stefan Norin et al.   LEUKEMIA RESEARCH

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

(2014) Charles H Pritchard et al.   BMC MUSCULOSKELETAL DISORDERS

Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma

(2014) Shaker Dakhil et al.   LEUKEMIA & LYMPHOMA

The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital

(2014) Jae-Woo Jung et al.   ONCOLOGY

Induction of Interleukin-6 Production by Rituximab in Human B Cells

(2014) Jonathan D. Jones et al.   Arthritis & Rheumatology

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma

(2013) Teresa Arredondo-Garza et al.   ARCHIVES OF MEDICAL RESEARCH

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

(2013) J. Golay et al.   BLOOD

Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab

(2012) Alessandra Vultaggio et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Rituximab in chronic lymphocytic leukemia

(2011) Danelle F. James et al.   ADVANCES IN THERAPY

Rapid Development of Infusion-Related Severe Hypotension During Rituximab Therapy

(2011) Kevin H Vo et al.   ANNALS OF PHARMACOTHERAPY

Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma†

(2011) Gillian M. Keating   BIODRUGS

Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis

(2011) F. Conti et al.   RHEUMATOLOGY

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis

(2010) Brandon A. Brown et al.   DRUG SAFETY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Monoclonal antibody-induced cytokine-release syndrome

(2009) Peter J Bugelski et al.   Expert Review of Clinical Immunology

Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction

(2008) Mark Wing   Journal of Immunotoxicology

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST